Celleurope
Marie Curie Initial Training Network

Research Topics


The research training programme involves 12 Marie Curie Fellows working together with different methodologies and datasets gathered in different countries and from multiple perspectives. The programme will provide an insight into the mechanisms of action of GvL and GvHD in order to improve current therapies and develop and test novel ones via clinical trials and/or animal model experiments.

On-the-job training will be supplemented with structured workshops concerning HSCT research and network-wide training on project management skills, ethics, regulatory issues and cross-national research to exploit the expertise of each partner.

In order to promote and evidence the impact of this research and training programme, all researchers and partners will guarantee societal dissemination of the results to a wider national and international audience.

Each fellow will deliver a project which is defined and embedded within a work package structure of the work programme and focused on one of the six research topics. Please see below for our research topics and the associated fellow research projects.

Predictive Biomarkers

Predicting GvHD and identification of novel biomarkers for GvHD.

Predicting GvHD by gene expression profiling and testing new targets

Assessment of Biomarkers

Monitoring GvHD and assessment of biomarkers for use post cellular therapy.

Monitoring biology of GvHD using biomarkers

Graft vs Leukemia (GvL)

GvL effects of NK cells against leukaemia cell lines.

Determining soluble serum markers and membrane bound NK-ligands for the prediction of antitumour immune GvL responses and GvHD

Animal Studies

Adaptive repertoire profiling.

Use of an animal model for studying GvHD/GvL and cellular therapies

Therapies

In vitro safety and efficacy assessment of novel therapeutics including antibodies, aptamers and cellular therapies by the use of a human in vitro skin explant model (Skimune™)

Cellular Therapies

CMV infection post HSCT.

Development of genetically modified Tcells to target leukemic cells

MSC’s as therapy for GvHD and regenerative medicine.